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Abstract Leptin, the product of the ob gene, controls appetite 
through the hypothalamus and may affect many other tissues 
because of the widespread distribution of its receptors. Leptin is 
synthesized by white adipose tissue (WAT) under conditions of 
high energy availability and insulin stimulus. Glucocorticoids 
enhance this synthesis and catecholamines hamper leptin 
production. Leptin diminishes insulin secretion by the pancreatic 
beta cells and induces insulin resistance. In fact leptin hampers 
insulin action on WAT itself in a negative feedback loop. The 
evidence acquired in studies on diabetics, starvation, refeeding 
and insulin and glucose clamps supports this interpretation, 
which may also explain part of the difficulties encountered by the 
current postulate that links leptin to WAT mass size signalling to 
the brain. Leptin may be, essentially, a counter-regulatory 
hormone limiting the insulin drive to store energy in the form of 
fat, its effects reaching from a decrease in food intake to lower 
insulin secretion and increased resistance to insulin and lower 
glucose uptake and fat synthesis by WAT. 
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1. Leptin expression in white adipose tissue 
The study of the mechanisms controlling body weight has 
received an enormous boost during the last year thanks to the 
identification of the ob gene and its product, leptin, which 
induces the loss of fat in ob/ob mice [1-3]. Leptin is expressed 
only in adipose tissues [4], though it is more intensely ex-
pressed in white than in brown adipose tissue [5]. 
The gene db, encoding the leptin receptor has been charac-
terized in mice [6], and in rats, where it has been found to 
coincide with the fa mutation [7]; its defect results in the 
overexpression of the ob gene [8]. Leptin down-regulates the 
expression of the ob gene via paracrine or endocrine path-
ways, since isolated adipocytes do not respond to direct leptin 
stimulation [9]. Sympathetic activity or cAMP lowers the ex-
pression of the ob gene [9]. In white adipose tissue, ß-adre-
nergic stimulation decreases ob gene expression [5]. Cold ex-
posure, directly related to sympathetic stimulation rewarming, 
also lowers the synthesis of leptin in adipose tissue, an effect 
that can be partially reversed by reheating [10]. 
In vivo leptin release by adipose tissue has been demon-
strated in humans and circulating leptin levels are correlated 
with degree of obesity [11], because of overexpression of the 
ob gene [12]. Leptin and insulin levels, as well as body weight, 
are inter-correlated [13]. However, non-insulin-dependent 
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diabetics show leptin levels which do not differ from those of 
non-diabetic humans of the same body mass index [14]. 
In normal rats, ob gene expression is down-regulated by 
insulinemia under euglycemic conditions [15]. The presence 
of insulin is also required for leptin release [16]. In streptozo-
tocin-diabetic rodents, however, the low levels of ob gene 
mRNA are not fully restored with continuous insulin treat-
ment in the way that glycemia and other markers are [17]. 
This has prompted the assumption that the ob gene is not, 
or is only minimally, regulated by insulin [17]. Obese mice are 
insensitive to insulin induction of leptin synthesis because of 
chronic exposure to both glucose and insulin [18]. Leptin se-
cretion also decreases during starvation [19], and increases 
with refeeding [20]. 
Hyperinsulinemia induces a rise in adipose tissue ob gene 
expression in humans [21], but euglycemic hyperinsulinemic 
and hypoglycemic clamps fail to alter leptin levels [21]. How-
ever, euglycemic insulin and hyperglycemic clamps resulted in 
increased leptin secretion [16]. Short-term insulin administra-
tion does not increase leptin secretion in humans [16,21], but 
insulin affects leptin levels in the long term [16]. The db/db 
(diabetic) mice, lacking a functional leptin receptor [22], show 
insulin resistance, overexpression of the ob gene [7], and other 
pathologies related to diabetes. The Zucker fa/fa rats, also 
defective in leptin receptors, do not present the modulation 
of leptin levels induced by starvation, insulin or cold exposure 
[23]. 
2. Is leptin a ponderostat signal? 
Leptin establishes a link between peripheral tissue-derived 
information and the central nervous system network [1]. Its 
main binding site in the brain is the choroid plexus [24]. Sys-
temic leptin lowers the hypothalamic expression of neuropep-
tide Y in ob/ob mice [26], which have abnormally raised levels 
of neuropeptide Y mRNA, but has no effect on the db/db 
mice, lacking functional leptin receptors [26]; overexpression 
of neuropeptide Y leads to increased appetite, hyperglycemia 
and obesity [26]. Thus, leptin injected into the hypothalamus 
inhibits neuropeptide Y synthesis and release [25]. Intracere-
broventricular injections of neuropeptide Y induce the expres-
sion of the ob gene [27] due to secondary hyperinsulinemia. 
The main role attributed to leptin is to act as a ponderostat 
signal which informs the brain of the mass of fat reserves [28]. 
However, there are a number of experimental results suggest-
ing that leptin does not fully comply with the requisites of a 
ponderostat signal as initially postulated [29]. There is a very 
wide variation in leptin levels in plasma [30], which in addi-
tion vary with fasting [19], fat-rich diets [31], carbohydrate 
ingestión [32] and alterations in blood glucose [18]. All these 
changes are related to the availability of energy. But leptin is 
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Fig. 1. Modulation of leptin synthesis in adipose tissue by insulin, 
glycemia, catecholamines and glucocorticoids. 
also sensitive to insulin [21], and is affected by glucocorticoids 
[33] and catecholamines [4] as well as by lipolysis metabolites 
such as fatty acids [34]. The hormones listed are precisely 
those which control the fate of the available energy, either 
by storing fat or by wasting through thermogenesis. 
Leptin mRNA levels are unaffected by the size of adipocyte 
fat stores [34], but leptin production is related to adipose 
tissue mass [12,30]. Starvation and loss of fat tissue both in-
duce decreases in circulating leptin and adipose tissue ob 
mRNA levels [18,19], but the post-slimming levels are lower 
than expected from the remaining body fat. The identification 
of transport systems helping to cross the blood-brain barrier 
has increased the possibility that leptin plays a role in the 
central nervous system [35]. Leptin transport into the CSF 
is diminished in the obese [36], which provides a basis for 
human leptin resistance such as that observed in children 
[37]. However, this transport into CSF is not unique, since 
it is shared by a number of peptide hormones, in particular 
insulin, which combine centrally induced effects with periph-
eral actions on metabolism [38] and a very direct implication 
on energy partition and the development of obesity. 
3. Insulin-leptin interrelationships 
The identification of a direct implication of leptin on adi-
pocyte lipid metabolism [39] raises the possibility that leptin 
may act directly as a hormone on other tissues, i.e. not 
through the brain-mediated circuits. There is a direct relation-
ship between insulin and leptin, but the latter only responds to 
the insulin stimulus under conditions of hyperglycemia or 
high availability of energy [21], since starvation lowers leptin 
production [19] and normoglycemic hyperinsulinemia fails to 
raise leptin levels [21]. Carbohydrate feeding increases leptin 
expression and circulating levels in rats [31]. Leptin is thus 
secreted when the metabolic signal 'high glucose availability' 
and the endocrine signal 'insulin' act at the same time, in a 
coordinated manner, marking a true situation of high lipo-
genic potentiality. In that case, we postulate that the produc-
tion of leptin may serve as a signal of a counter-regulatory 
mechanism preventing the excessive incorporation of reserves 
into adipocytes (Fig. 1). Hence its effects in diminishing the 
additional intake of energy and its widely accepted definition 
as a satiation factor [40], as well as the potentiation of energy 
expenditure [3], probably mediated through noradrenergic 
pathways [9]. In addition to these central effects, leptin acts 
on adipose tissue metabolism, and perhaps on other tissues, 
since they contain abundant leptin receptors in different struc-
tural forms [41]. The consequence of leptin action is the in-
duction of insulin resistance, a diabetogenic trait characteriz-
ing db/db mice. In this way leptin tends to diminish the 
combined effects of insulin and high energy that initially elic-
ited its secretion. 
The effects of leptin on other systems and pathways (cyto-
kines, nerve growth factor, etc.), in spite of our sketchy 
knowledge of them, may give support to a major role for 
leptin as a counter-regulatory hormone (or paracrine factor 
acting on adipose tissue itself) which protects adipose tissue 
(and perhaps other organs and tissues) from excessive lipid 
synthesis induced by high insulin and ample energy availabil-
ity. 
Leptin receptors have been characterized in ß-cells, which 
allows for negative insulin synthesis feedback [42]. Insulin, in 
parallel with leptin, is also found in the brain [38] and is also 
transported by means of a saturable system [43], through the 
arcuate nucleus [44] acting on the neuropeptide Y levels [44]. 
Insulin thus exerts central actions which are complementary 
to the peripheral effects on tissues [38]. Obese humans are 
often hyperinsulinemic and show resistance to insulin [45] in 
parallel with raised leptin levels [4,20,30]. The latter decrease 
when weight is lost or food intake is limited [17,19], situations 
in which insulin and energy availability (glycemia) are de-
creased, and as a result insulin resistance decreases. It can 
be postulated, then, that leptin may be a key factor in the 
development of insulin resistance in the same way as that 
found in the db/db mice. 
4. Concluding remarks 
The changes observed with starvation [19], light cycles [46] 
and cold exposure [5,10] suggest further modulation by glu-
cocorticoids potentiating leptin production [9,33,34] and cate-
cholamines inhibiting its synthesis through modulation of 
cAMP levels [9] or lipolysis-derived fatty acids [34]. In any 
case, this very important role could not coexist nor coincide 
with the signalling to the brain of body fat mass, and thus we 
ought to see leptin in the light of a counter-regulatory hor-
mone affecting body weight, not simply as a long-term signal. 
Thus, perhaps leptin will not in the end turn out to be the 
long-sought ponderostat signal. Nevertheless, leptin is a 
powerful satiation factor and very probably a key insulin 
counter-regulatory hormone, playing a role - in itself perhaps 
more important than that of a ponderostat signal - of para-
mount importance for the understanding of the molecular 
mechanisms determining not only obesity and energy parti-
tion, but also diabetes. 
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